Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
详细信息 查看全文
- 作者：Adil Daud ; Japinder Gill ; Sheily Kamra ; Lei Chen…
- 关键词：Dabrafenib ; Trametinib ; Vemurafenib ; Cobimetinib ; Metastatic melanoma ; Indirect treatment comparison
- 刊名：Journal of Hematology & Oncology
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：10
- 期：1
- 全文大小：479KB
- 刊物主题：Oncology; Hematology; Cancer Research;
- 出版者：BioMed Central
- ISSN：1756-8722
- 卷排序：10
文摘
BackgroundMetastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies. The introduction of BRAF/MEK inhibitor combinations has yielded significant increases in PFS and OS for melanoma. However, at present, no direct comparisons between different BRAF/MEK combinations have been conducted. In light of this, an indirect treatment comparison was performed between two BRAF/MEK inhibitor combination therapies for metastatic melanoma, dabrafenib plus trametinib and vemurafenib plus cobimetinib, in order to understand the relative efficacy and toxicity profiles of these therapies.